Sen­ti Bio of­floads man­u­fac­tur­ing site to Hong Kong PE firm for $38M

San Fran­cis­co-based pre­clin­i­cal biotech Sen­ti Bio­sciences is sell­ing off a man­u­fac­tur­ing fa­cil­i­ty to a pri­vate eq­ui­ty firm that’s spin­ning it in­to a new con­tract man­u­fac­tur­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER